These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 2477146)

  • 1. Sequence and schedule-dependent synergy of trimetrexate in combination with 5-fluorouracil in vitro and in mice.
    Elliott WL; Howard CT; Dykes DJ; Leopold WR
    Cancer Res; 1989 Oct; 49(20):5586-90. PubMed ID: 2477146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic synergy of trimetrexate (CI-898) in combination with doxorubicin, vincristine, cytoxan, 6-thioguanine, cisplatin, or 5-fluorouracil against intraperitoneally implanted P388 leukemia.
    Leopold WR; Dykes DJ; Griswold DP
    NCI Monogr; 1987; (5):99-104. PubMed ID: 2963231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo.
    Elliott WL; Roberts BJ; Howard CT; Leopold WR
    Cancer Res; 1994 Aug; 54(16):4412-8. PubMed ID: 8044790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of trimetrexate cytotoxicity in vitro and in vivo by carboxypeptidase G2.
    Romanini A; Sobrero AF; Chou TC; Sherwood RF; Bertino JR
    Cancer Res; 1989 Nov; 49(21):6019-23. PubMed ID: 2529027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro synergism between 5-fluorouracil and natural beta interferon in human colon carcinoma cells.
    Guglielmi A; Aschele C; Mori A; Baldo C; Russo P; Debernardis D; Valenti M; Bruno S; Taverna M; Rosso R
    Clin Cancer Res; 1995 Nov; 1(11):1337-44. PubMed ID: 9815929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pretreatment of colon carcinoma cells with Tomudex enhances 5-fluorouracil cytotoxicity.
    Longo GS; Izzo J; Chang YM; Tong WP; Zielinski Z; Gorlick R; Chou TC; Bertino JR
    Clin Cancer Res; 1998 Feb; 4(2):469-73. PubMed ID: 9516938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity and biochemical effects of aphidicolin glycinate (NSC 303812) alone and in combination with cisplatin in vivo.
    O'Dwyer PJ; Moyer JD; Suffness M; Harrison SD; Cysyk R; Hamilton TC; Plowman J
    Cancer Res; 1994 Feb; 54(3):724-9. PubMed ID: 8306334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trimetrexate: clinical development of a nonclassical antifolate.
    O'Dwyer PJ; DeLap RJ; King SA; Grillo-Lopez AJ; Hoth DF; Leyland-Jones B
    NCI Monogr; 1987; (5):105-9. PubMed ID: 2963228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration.
    Bible KC; Kaufmann SH
    Cancer Res; 1997 Aug; 57(16):3375-80. PubMed ID: 9269999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic growth inhibition of rat hepatoma cells exposed in vitro to N10-propargyl-5,8-dideazafolate with methotrexate or the lipophilic antifolates trimetrexate or metoprine.
    Galivan J; Nimec Z; Rhee M
    Cancer Res; 1987 Oct; 47(20):5256-60. PubMed ID: 2958130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implications for improved high-dose methotrexate therapeutic effects in cultured human breast cancer and bone marrow cells.
    Bowen D; Southerland WM; Johnson DH; Hawkins M; Hughes DE
    Cancer Detect Prev; 2000; 24(5):452-8. PubMed ID: 11129987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemoimmunotherapy of B 16 melanoma and P388 leukemia with cyclophosphamide and pyrimidinones.
    Li LH; Johnson MA; Moeller RB; Wallace TL
    Cancer Res; 1984 Jul; 44(7):2841-7. PubMed ID: 6722813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal schedule of methotrexate and 5-fluorouracil in human breast cancer.
    Benz C; Tillis T; Tattelman E; Cadman E
    Cancer Res; 1982 May; 42(5):2081-6. PubMed ID: 6175406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Schedule-dependent synergism and antagonism between paclitaxel and methotrexate in human carcinoma cell lines.
    Kano Y; Akutsu M; Tsunoda S; Furuta M; Yazawa Y; Ando J
    Oncol Res; 1998; 10(7):347-54. PubMed ID: 10063968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination chemotherapy with a new folate analog: activity of 10-ethyl-10-deaza-aminopterin compared to methotrexate with 5-fluorouracil and alkylating agents against advanced metastatic disease in murine tumor models.
    Schmid FA; Sirotnak FM; Otter GM; DeGraw JI
    Cancer Treat Rep; 1987; 71(7-8):727-32. PubMed ID: 3607784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular chemotherapy combined with radiation therapy enhances killing of cholangiocarcinoma cells in vitro and in vivo.
    Pederson LC; Buchsbaum DJ; Vickers SM; Kancharla SR; Mayo MS; Curiel DT; Stackhouse MA
    Cancer Res; 1997 Oct; 57(19):4325-32. PubMed ID: 9331094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of combined therapy with methotrexate and 5-fluorouracil from the view point of cellular PRPP level of L1210 cells and HeLa S3 cells.
    Kakuta H; Kanamaru R; Sato T; Ishioka C; Wakui A
    Sci Rep Res Inst Tohoku Univ Med; 1985 Dec; 32(1-4):47-52. PubMed ID: 2428109
    [No Abstract]   [Full Text] [Related]  

  • 19. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.
    Beland FA
    Toxic Rep Ser; 1999 Aug; (59):1-66, A1-E7. PubMed ID: 11803702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytotoxic synergy between pyrazoloacridine (NSC 366140) and cisplatin in vitro: inhibition of platinum-DNA adduct removal.
    Adjei AA; Budihardjo II; Rowinsky EK; Kottke TJ; Svingen PA; Buckwalter CA; Grochow LB; Donehower RC; Kaufmann SH
    Clin Cancer Res; 1997 May; 3(5):761-70. PubMed ID: 9815747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.